Recently, another well done study of vitamin D and cancer resulted in disappointing results. Vitamin D supplements showed no benefit in persons with metastatic colorectal cancer (CRC). It did not result in a difference in overall survival outcomes.
In the study, 455 patients with metastatic colorectal cancer were assigned randomly to either high daily vitamin D3 or standard dose vitamin D3, in addition to receiving standard chemotherapy. The high dose vitamin D group received a loading dose of 8000 IU per day for 2 weeks, followed by a maintenance dose of 4000 IU per day until the end of the study. The standard dose vitamin D group received 400 IU per day.
However, there was no difference in "significant progression-free survival benefit". There also was no significant difference in how long people survived in the 2 groups (a median of 25.6 months in the high-dose group, and 27.0 months in the standard dose group).
The study results were disappointing because in laboratory studies vitamin D has anticancer properties. Critics of this study pointed out that vitamin D supplementation may have a role in cancer prevention - but at this point, that is unknown.
From Medscape: High-Dose Vitamin D Disappoints in Metastatic CRC: SOLARIS
The addition of high-dose vitamin D supplementation to standard chemotherapy plus bevacizumab did not result in a significant progression-free survival benefit in patients with metastatic colorectal cancer (CRC) in the SOLARIS study. ...continue reading "Another Vitamin D Study With Disappointing Results"